ESC Congress 2025 - Long-term beta-blocker therapy after myocardial infarction reduced the primary endpoint of death from any cause or major adverse cardiovascular events.

Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Dan Atar (Oslo University Hospital Ulleval, NO) and Dr Anna Meta Dyrvig Kristensen (Bispebjerg and Frederiksberg Hospital, DK) to discuss the latest findings from the combined BETAMI-DANBLOCK trial evaluating beta-blocker therapy after myocardial infarction.

This landmark event-driven trial represents the largest modern evaluation of beta-blocker efficacy in post-MI patients, combining the Danish DANBLOCK and Norwegian BETAMI studies to randomise approximately 5,700 patients with normal or mildly reduced left ventricular ejection fraction (LVEF ≥ 40%) to open-label beta-blocker therapy or no such treatment.

Findings presented first at ESC.25 showed that when administered within 14 days of MI, long-term beta-blocker therapy was found to reduce death from any cause or major adverse cardiovascular events.

Recorded onsite at ESC Congress 2025 in Madrid.

Editors: Jordan Rance and Yazmin Sadik.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.